Publications by authors named "J Luthman"
Preclinical target validation for non-addictive therapeutics development for pain.
Expert Opin Ther Targets
September 2022
Introduction: The Helping to End Addiction Long-term Initiative supports a wide range of programs to develop new or improved prevention and opioid addiction treatment strategies. An essential component of this effort is to accelerate development of non-opioid pain therapeutics. In all fields of medicine, therapeutics development is an arduous process and late-stage translational efforts such as clinical trials to validate targets are particularly complex and costly.
View Article and Find Full Text PDFIntroduction: Cerebrospinal fluid (CSF) biomarkers can identify individuals with Alzheimer's disease (AD) pathology (eg, amyloid plaques, neurofibrillary tangles), but defined analyte cut-points using high-throughput automated assays are necessary for general clinical use.
Methods: CSF amyloid β42 peptide (Aβ42), t-tau, and t-tau/Aβ42 were quantified by the Lumipulse platform in two test cohorts (A/B: Eisai BAN2401-201/MISSION AD E2609-301/302, n = 138; C: Knight Alzheimer's Disease Research Center (ADRC), n = 198), and receiver operating characteristic (ROC) curve analyses defined cut-points corresponding best to amyloid determinations using positron emission tomography (PET) imaging. The best-performing cut-point was then validated as a predictor of amyloid status in an independent cohort (D: MISSION AD E2609-301/302, n = 240).
Article Synopsis
- A study was conducted to evaluate the impact of implantable cardioverter defibrillators (ICDs) on patients with continuous flow left ventricular assist devices (LVADs), using data from the Cleveland Clinic between 2004 and 2017.
- Of the 486 patients analyzed, 79.6% had ICDs prior to LVAD implantation, but the study found no significant associations between the use of ICDs and mortality rates.
- The findings suggest that while ICDs are associated with various complications and procedures, they do not provide a mortality benefit for patients with continuous flow LVADs.
The convergence of human molecular genetics and Lewy pathology of Parkinson's disease (PD) have led to a robust, clinical-stage pipeline of alpha-synuclein (α-syn)-targeted therapies that have the potential to slow or stop the progression of PD and other synucleinopathies. To facilitate the development of these and earlier stage investigational molecules, the Michael J. Fox Foundation for Parkinson's Research convened a group of leaders in the field of PD research from academia and industry, the Alpha-Synuclein Clinical Path Working Group.
View Article and Find Full Text PDF